Sorry, you need to enable JavaScript to visit this website.

Seng H Cheng, Ph.D.

Senior Vice President & Chief Scientific Officer, Rare Disease


I joined Pfizer in 2018 as Senior Vice President & Chief Scientific Officer of the Rare Disease Research Unit. I am responsible for setting the strategy to build a leading rare disease R&D pipeline by developing solutions that profoundly improve the health of patients.

I obtained my BSc and PhD in Biochemistry at the University of London and trained as a postdoctoral fellow with Dr. Alan E. Smith at the National Institute of Medical Research, U.K., in the field of tumor biology.

Prior to joining Pfizer, I was a Group Vice President of Genetic Diseases Science at Genzyme for 25 years researching solutions for patients with rare diseases, notably lysosomal storage disorders and cystic fibrosis. Most recently, I was the Global Head of Research of Rare Diseases at Sanofi leading researchers in the pursuit of transformative treatments for patients living with metabolic, neurological, neuromuscular, renal, pulmonary and hematological diseases. During my tenure at these organizations, I gained experience in ideating and developing projects from discovery research through to clinical development and approval.

Key accomplishments:

Notable scientific contributions include demonstrating the role of phosphorylation in regulating the tyrosine kinase activity of proto-oncogenes and elucidating the underlying molecular basis for the most common form of cystic fibrosis. I have co-authored 278 research articles and reviews, and is a named co-inventor on 57 issued US patents in the area of biotechnology.


As the Chief Scientific Officer, Rare Disease at Pfizer, I am charged with building upon the foundation of rare disease-associated initiatives at Pfizer, with emphasis on gene therapy as an emerging therapeutic paradigm. We aspire to consolidate our leadership in non-malignant hematological and inherited metabolic diseases and expand our presence in rare neurological and cardiological diseases. In addition to these core areas of focus, the Rare Disease Research Unit will explore opportunities that afford solutions for patients with rare nephrological, and pulmonary diseases.


  1. Glucosylceramide synthase inhibition alleviates aberrations in synucleinopathy models. Proc. Natl. Acad. Sci. USA 2017, 114:2699-2704 Sardi, SP, Viel, C, Clarke, J, Treleaven, CM, Richards, AM, Park, H, Olszewski, MA, Dodge, JC, Marshall, J, Makino, E, Wang, B, Sidman, RL, Cheng, SH, and Shihabuddin, LS.
  2. Intravitreous injection of AAV2.sFLT01 in patients with advanced neovascular age-related macular degeneration: a phase 1 open-label trial. Lancet 2017; 390:50-61. Heier, JS, Kherani, S, Desai, S., Dugel, P, Kaushal, S, Cheng, SH, Delacono, C, Purvis, A, Richards, S, Le-Halpere, A, Connelly, J, Wadsworth, SC, Varona, R, Buggage, R, Scaria, A, Campochiaro, PA.
  3. Fetal gene therapy for neurodegenerative disease of infants. Nature Med. 2018; 24:1317-1323. Rahim, AA, Mattar, CN, Wong, AMS, Massaro, G, Sirka, E, Buckley, SMK, Herbert, BR, Karlsson, S, Perocheau, DP, Burke, D, Heales, S, Richard-Londt, A, Brandner, S, Hubecker, M, Priestman, DM, Platt, FM, Mills, K, Biswas, A, Cooper, JD, Chan, JKY, Cheng, SH, and Waddington, SN.
  4. Inhibiting neutral amino acid transporter for the treatment of phenylketonuria. JCI Insight 2018; 3:e121762 Belanger, AM, Przybylska, M, Gefteas, E, Furgerson, M, Geller, S, Kloss, A, Cheng, SH, and Zhu, Y, and Yew, NS.
  5. Adeno-associated viral vector serotype 9-based gene therapy for Niemann-Pick disease type A. Sci. Transl. Med. 2019; 11:eaat3738. Samaranch, L., Perez-Canamas, A., Soto-Huelin, B., Sudhakar, V., Jurado-Arjona, J., Hadaczek, P., Avila, J., Bringas, J.R., Casas, J., Chen, H., He, X., Schuchman, E.H., Cheng, S.H., Forsayeth, J., Bankiewicz, K.S., and Ledesma, M.D.
  6. Bispecific antibody-mediated restroration of the linkage between dystroglycan and laminin-211 as a therapeutic approach for a-dystroglycanopathies. Mol. Ther. 2020; 28:664-676. Gumlaw, N., Sevigny, L.M., Zhao, H., Luo, Z., Bangari, D.S., Masterjohn, E., Chen, Y., McDonald, B., Magnay, M., Travaline, T., Yoshida-Moriguchi, T., Fan, W., Reczek, D., Stefano, J.E., Qiu, H., Beil, C., Lange, C., Rao, E., Lukason, M., Barry, E., Brondyk, W.H., Zhu, Y., and Cheng, S.H.


University of London, UK, Biochemistry, BSc, 1979
University of London, UK, Biochemistry, PhD, 1983
National Institute of Medical Research, London, Biochemistry, Postdoctoral Fellow, 1985


College Scholarship from the University of London, UK, 1979
Postdoctoral Fellowship from the Medical Research Council, London, UK, 1983
Genzyme Vice-President's Achievement Award, 1994
Genzyme President's Eagle Achievement Award, 1996

Media Name: k_beaverson300x170.jpg
Katherine L Beaverson, M.S.

Executive Director, Patient Advocacy Lead

Media Name: binks300x170.jpg
Michael Binks, M.D.

Vice President, Clinical Research

Media Name: christian_czech300x170.jpg
Christian Czech, PH.D.

Senior Director, Biology and Nice Site Lead

Media Name: grimwood300x170.jpg
Sarah Grimwood, Ph.D.

Executive Director, Head of Portfolio, Strategy & Operations

Media Name: LaRosa_21_300x170.jpg
Greg LaRosa, Ph.D.

Vice President, Head of Scientific Research

Media Name: clark_pan_300x170.jpg
Clark Pan, PH.D.

Vice President, Gene Therapy and Discovery Biology

Ken Rhodes, Ph.D.

Vice President, Rare Neurology and Discovery Biology